#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18288	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2671	844.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	2039	2039	T	1197	T,G,A	1195,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18288	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2671	844.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1773	1773	C	1175	C	1175	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18288	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2671	844.0	0	HET	.	.	.	A69G	.	69	69	A	658	658	A	1204	A,G	934,267	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	18288	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2671	844.0	0	HET	.	.	.	C262T,A	.	262	262	C	851	851	C	1134	C,T,A	868,262,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3973	969.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1862	1862	A	1274	A	1274	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3973	969.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2496	2496	C	1081	C,A,T	1078,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3973	969.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2570	2570	A	942	A,C	941,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30932	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3973	969.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3122	3122	C	1083	C,A	1078,3	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2688	folP	852	852	99.88	folP.l15.c4.ctg.1	1909	175.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	982	984	AAA	268;269;270	A;A;A	268;269;270	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2688	folP	852	852	99.88	folP.l15.c4.ctg.1	1909	175.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1213	1215	AGC	290;293;291	A,G;G;C,T	289,1;293;290,1	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6492	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3844	210.5	1	SNP	p	S91F	0	.	.	271	273	TCC	820	822	TCC	248;247;247	T;C;C,A	248;247;246,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6492	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3844	210.5	1	SNP	p	D95N	0	.	.	283	285	GAC	832	834	GAC	250;251;250	G,T;A;C,A	249,1;251;249,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6492	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3844	210.5	1	SNP	p	D95G	0	.	.	283	285	GAC	832	834	GAC	250;251;250	G,T;A;C,A	249,1;251;249,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2522	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1970	159.6	1	SNP	p	G45D	0	.	.	133	135	GGC	870	872	GGC	291;294;293	G;G;C	291;294;293	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1412	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1349	129.9	0	.	n	.	0	A197.	DEL	197	197	A	802	802	A	292	A	291	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6342	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3405	232.3	1	SNP	p	D86N	0	.	.	256	258	GAC	805	807	GAC	278;277;278	G;A,C;C	278;275,2;278	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6342	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3405	232.3	1	SNP	p	S87I	0	.	.	259	261	AGT	808	810	AGT	276;276;275	A;G;T,C	276;276;274,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6342	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3405	232.3	1	SNP	p	S87R	0	.	.	259	261	AGT	808	810	AGT	276;276;275	A;G;T,C	276;276;274,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6342	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3405	232.3	1	SNP	p	S87W	0	.	.	259	261	AGT	808	810	AGT	276;276;275	A;G;T,C	276;276;274,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6342	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3405	232.3	1	SNP	p	S88P	0	.	.	262	264	TCC	811	813	TCC	273;273;273	T;C,A;C	273;272,1;273	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5288	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3157	209.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1857	1859	GGC	304;301;298	G,A;G,A;C	303,1;300,1;298	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1475	1477	GCA	287;291;295	G;C;A	287;291;295	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1478	1480	ATC	295;298;301	A,G,C;T;C,G	293,1,1;298;300,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1490	1492	GTG	298;295;293	G,A;T;G,T	297,1;295;292,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1490	1492	GTG	298;295;293	G,A;T;G,T	297,1;295;292,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1994	1996	ACC	277;277;278	A,C,G;C;C	274,2,1;277;278	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2048	2050	GCG	269;270;269	G;C,T;G	269;269,1;269	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2048	2050	GCG	269;270;269	G;C,T;G	269;269,1;269	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2171	2173	GGC	258;259;261	G;G;C,T	258;259;260,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2180	2182	GGC	268;269;271	G,C;G;C,A,G	267,1;269;269,1,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4868	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2995	202.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2198	2200	CTG	269;266;264	C;T,C,G;G	269;264,1,1;264	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6718	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3591	233.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1843	1845	CCG	257;257;254	C,A;C,T;G,C	256,1;256,1;253,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2950	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2237	164.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	803	803	C	236	C	236	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	100	95.0	porB1a.l15.c17.ctg.2	181	51.1	0	.	p	.	0	M18T	NONSYN	52	54	ATG	132	134	ACG	62;62;56	A;C;G,C	62;62;55,1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	100	95.0	porB1a.l15.c17.ctg.2	181	51.1	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	174	176	CAA	15;11;11	C;A;A	15;11;11	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	37;38;41	T;T;A	37;38;41	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	80;80;80	C,A;A;T	79,1;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	80;80;80	A;G;T	80;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	80;80;80	T;A;C	80;80;80	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	3;3;4	G;A;C	3;3;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	5;5;5	T;C;G	5;5;5	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	5;5;5	A;G;C	5;5;5	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	332	porB1a	984	226	90.27	porB1a.l15.c17.ctg.3	309	36.4	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	5;5;5	G;T;T	5;5;5	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	536	538	GAA	322;323;322	G;A;A	322;323;322	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	824	826	GAT	283;283;280	G;A;T	283;283;280	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	947	949	TCA	340;339;340	T;C,A;A	340;338,1;340	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1076	1078	GTC	334;329;326	G,A;T;C	333,1;329;326	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1406	1408	GCA	329;331;332	G,C;C,A;A,C	328,1;330,1;331,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	1	SNP	p	G120K	1	.	.	358	360	AAG	782	784	AAG	282;284;281	A,T;A;G	281,1;284;281	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	1	SNP	p	D121N	0	.	.	361	363	GAC	785	787	GAC	281;283;285	G,T;A;C,A	279,2;283;284,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3646	porB1b	1047	1047	99.33	porB1b.l15.c17.ctg.1	1808	248.3	1	SNP	p	A121D	1	.	.	361	363	GAC	785	787	GAC	281;283;285	G,T;A;C,A	279,2;283;284,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11992	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5390	277.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2357	2359	AAT	318;319;317	A;A;T	318;319;317	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1774	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1605	138.0	1	SNP	p	V57M	1	.	.	169	171	ATG	769	771	ATG	328;326;327	A;T;G	328;326;327	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
